Painkillers Market Analysis

 Product (OTC Products, Prescription Drugs)

OTC segment is set to dominate around 52.7% painkillers market share by the end of 2037. The general availability of these drugs has reduced the extensive cost of doctor visits for non-critical pain management. This has further propelled the demand for OTC supplements in use for mild to moderate pain such as headaches, muscle aches, back pain, and other minor injuries. Companies are producing various forms including Acetaminophen, NSAIDs, topical agencies, and hybrid drugs. For instance, in March 2020, GSK received FDA approval for Advil Dual Action, a combination of ibuprofen and acetaminophen to be circulated for pain relief. Such diversity makes them applicable to curing a wide range of pain or discomfort, promoting its effectiveness.

Drug Class (Opioids, Tramadol, Oxycodone, Hydrocodone, Other Opioids, NSAIDs, Local Anesthetics, Acetaminophen)

Based on drug class, the painkillers market is projected to experience great development in the local anesthetics segment by 2037. The growth is owed to the increasing rate of surgical interventions in every medical category. Being a crucial part of performing surgical and dental procedures without causing pain, has accelerated the demand for this segment. These also have a usage in chronic pain conditions, making them more desirable for effective post or non-operative management. Companies are now developing new formulations to acquire elongated and targeted impact, improving patient outcomes. For instance, in May 2021, Heron launched its FDA-approved ZYNRELEF for full-fledged use in managing post-operational pain. The dual-acting local anesthetic can serve for 72 hours duration after bunionectomy.

Our in-depth analysis of the painkillers market includes the following segments: